APRAMEYA vs KPL: Stock Comparison
KWALITY PHARMACEUTICALS L is the larger company by market capitalisation. APRAMEYA shows lower leverage, while KWALITY PHARMACEUTICALS L shows a lower P/E, a higher ROE and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APRAMEYA leads 4; KPL leads 6 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | APRAMEYA | KPL |
|---|---|---|
| Live Price | — | ₹3,471.2 |
| Day Change | — | 0.55% |
| Volume | — | 28,652 |
| 52-Week High | — | ₹3,798.9 |
| 52-Week Low | — | ₹1,561 |
| Distance from 52W High | — | -8.63% |
Valuation
| Metric | APRAMEYA | KPL |
|---|---|---|
| Market Cap | ₹217 Cr | ₹3,600 Cr |
| P/E Ratio | 60.82x | 44.42x |
| P/B Ratio | 0x | 10.86x |
| EPS | ₹2.68 | ₹24.7 |
| Book Value | ₹36.54 | ₹317.96 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | APRAMEYA | KPL |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0.7% | 0% |
| Qtr Profit Growth | 1.73% | -0.02% |
Profitability & Leverage
| Metric | APRAMEYA | KPL |
|---|---|---|
| ROE | 7.37% | 20.2% |
| ROCE | 10.07% | 16.32% |
| Net Margin | 0% | 13.39% |
| Operating Margin | 19.83% | 19.97% |
| Debt to Equity | 0.1x | 0.39x |
Shareholding
As of Mar 2026 • change vs previous quarter| Metric | APRAMEYA | KPL |
|---|---|---|
| Promoter Holding | 74.05%▲ 0.52 pp | 54.86%▼ 0.01 pp |
| FII Holding | 0% | 3.13%▲ 0.34 pp |
| DII Holding | 0.7%▼ 0.07 pp | 0.56%▲ 0.2 pp |
| Public Holding | 25.24%▼ 0.46 pp | 41.44%▼ 0.54 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: APRAMEYA and KWALITY PHARMACEUTICALS L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.